Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters

Authors: Marjolaine Ngollo, Andre Lebert, Aslihan Dagdemir, Gaelle Judes, Seher Karsli-Ceppioglu, Marine Daures, Jean-Louis Kemeny, Frederique Penault-Llorca, Jean-Paul Boiteux, Yves-Jean Bignon, Laurent Guy, Dominique Bernard-Gallon

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

It is well established that genetic and epigenetic alterations are common events in prostate cancer, which may lead to aberrant expression of critical genes. The importance of epigenetic mechanisms in prostate cancer carcinogenesis is increasingly evident. In this study, the focus will be on histone modifications and the primary objectives are to map H3K27me3 marks and quantify RAR beta 2, ER alpha, SRC3, RGMA, PGR, and EZH2 gene expressions in prostate cancer tissues compared to normal tissues. In addition, a data analysis was made in connection with the clinicopathological parameters.

Methods

71 normal specimens and 66 cancer prostate tissues were randomly selected in order to assess the proportion of the repressive H3K27me3 mark and gene expression. H3K27me3 level was evaluated by ChIP-qPCR and mRNA expression using RT-qPCR between prostate cancer and normal tissues. Subsequently, western-blotting was performed for protein detection. The analysis of variance (ANOVA) was performed, and Tukey’s test was used to correct for multiple comparisons (p-value threshold of 0.05). The principal component analysis (PCA) and discriminant factorial analysis (DFA) were used to explore the association between H3K27me3 level and clinicopathological parameters.

Results

The study demonstrated that H3K27me3 level was significantly enriched at the RAR beta 2, ER alpha, PGR, and RGMA promoter regions in prostate cancer tissues compared to normal tissues. After stratification by clinicopathological parameters, the H3K27me3 level was positively correlated with Gleason score, PSA levels and clinical stages for RAR beta 2, ER alpha, PGR, and RGMA. High H3K27me3 mark was significantly associated with decreased RAR beta 2, ER alpha, PGR and RGMA gene expressions in prostate cancer sample compared to the normal one. Moreover, the results showed that mRNA level of EZH2, AR and SRC3 are upregulated in prostate cancer compared to normal prostate tissues and this correlates positively with Gleason score, PSA levels and clinical stages. Obviously, these observations were confirmed by protein level using western-blot.

Conclusions

This data clearly demonstrated that H3K27me3 level correlated with aggressive tumor features. Also this study revealed that reverse correlation of RAR beta 2, ER alpha, PGR, and RGMA expressions with EZH2, SRC3, and AR expressions in prostate cancer tissues suggests that these genes are the target of EZH2. Therefore, all therapeutic strategies leading to histone demethylation with epigenetic drugs such as histone methyltransferase inhibitor may be relevant treatments against prostate cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Majumdar S, Buckles E, Estrada J, Koochekpour S: Aberrant DNA methylation and prostate cancer. Curr Genomics. 2011, 12: 486-505. 10.2174/138920211797904061.CrossRefPubMedPubMedCentral
3.
Adjakly M, Bosviel R, Rabiau N, Boiteux J-P, Bignon Y-J, Guy L, Bernard-Gallon D: DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics. 2011, 3: 795-803. 10.2217/epi.11.103.CrossRefPubMed
4.
Dagdemir A, Durif J, Ngollo M, Bignon Y-J, Bernard-Gallon D: Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics. 2013, 5: 51-63. 10.2217/epi.12.74.CrossRefPubMed
5.
Rabiau N, Trraf H-K, Adjakly M, Bosviel R, Guy L, Fontana L, Bignon Y-J, Bernard-Gallon DJ: miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo. 2011, 25: 917-921.PubMed
6.
7.
8.
Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH-M, Issa J-PJ: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008, 40: 741-750. 10.1038/ng.159.CrossRefPubMed
9.
10.
11.
Cavalli G: Molecular biology. EZH2 goes solo. Science. 2012, 338: 1430-1431. 10.1126/science.1232332.CrossRefPubMed
12.
Varambally S, Cao Q, Mani R-S, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322: 1695-1699. 10.1126/science.1165395.CrossRefPubMedPubMedCentral
13.
Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM: Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011, 2: 669-683.CrossRefPubMedPubMedCentral
14.
Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang B-D, Andrawis R, Lee NH, Apprey V, Issa J-P, Ittmann M: Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res Off J Am Assoc Cancer Res. 2010, 16: 3539-3547. 10.1158/1078-0432.CCR-09-3342.CrossRef
15.
Moison C, Senamaud-Beaufort C, Fourrière L, Champion C, Ceccaldi A, Lacomme S, Daunay A, Tost J, Arimondo PB, Guieysse-Peugeot A-L: DNA methylation associated with polycomb repression in retinoic acid receptor β silencing. FASEB J Off Publ Fed Am Soc Exp Biol. 2013, 27: 1468-1478.
16.
Nishimori H, Ehata S, Suzuki HI, Katsuno Y, Miyazono K: Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J Biol Chem. 2012, 287: 20037-20046. 10.1074/jbc.M112.353094.CrossRefPubMedPubMedCentral
17.
Li J, Ye L, Kynaston HG, Jiang WG: Repulsive guidance molecules, novel bone morphogenetic protein co-receptors, are key regulators of the growth and aggressiveness of prostate cancer cells. Int J Oncol. 2012, 40: 544-550.PubMed
18.
Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M: Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001, 61: 1919-1926.PubMed
19.
Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, Bishop MC, Rees RC: Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue. The Prostate. 2009, 69: 810-819. 10.1002/pros.20929.CrossRefPubMed
20.
Zhou H-J, Yan J, Luo W, Ayala G, Lin S-H, Erdem H, Ittmann M, Tsai SY, Tsai M-J: SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005, 65: 7976-7983.PubMed
21.
Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature. 2007, 447: 433-440. 10.1038/nature05919.CrossRefPubMed
22.
Rabiau N, Thiam MO, Satih S, Guy L, Kemeny J-L, Boiteux J-P, Fontana L, Bignon Y-J, Bernard-Gallon D: Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo. 2009, 23: 387-391.PubMed
23.
Vardi A, Bosviel R, Rabiau N, Adjakly M, Satih S, Dechelotte P, Boiteux J-P, Fontana L, Bignon Y-J, Guy L, Bernard-Gallon DJ: Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo. 2010, 24: 393-400.PubMed
24.
Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005, 435: 1262-1266. 10.1038/nature03672.CrossRefPubMed
25.
Ngollo M, Dagdemir A, Judes G, Kemeny J-L, Penault-Llorca F, Boiteux J-P, Lebert A, Bignon Y-J, Guy L, Bernard-Gallon D: Epigenetics of Prostate Cancer: Distribution of Histone H3K27me3 Biomarkers in Peri-Tumoral Tissue. Omics. 2014, 18: 207-209. 10.1089/omi.2013.0117.CrossRefPubMed
26.
Steiner I, Jung K, Schatz P, Horns T, Wittschieber D, Lein M, Dietel M, Erbersdobler A: Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. Pathobiol J Immunopathol Mol Cell Biol. 2010, 77: 260-266. 10.1159/000318017.CrossRef
27.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RGAB, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002, 419: 624-629. 10.1038/nature01075.CrossRefPubMed
28.
29.
Rabiau N, Déchelotte P, Adjakly M, Kemeny J-L, Guy L, Boiteux J-P, Kwiatkowski F, Bignon Y-J, Bernard-Gallon D: BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection. Oncol Rep. 2011, 26: 695-702.PubMed
30.
Prins GS, Korach KS: The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008, 73: 233-244. 10.1016/j.steroids.2007.10.013.CrossRefPubMed
31.
Rabiau N, Dantal Y, Guy L, Ngollo M, Dagdemir A, Kemeny J-L, Terris B, Vieillefond A, Boiteux J-P, Bignon Y-J, Bernard-Gallon D: Gene panel model predictive of outcome in patients with prostate cancer. Omics J Integr Biol. 2013, 17: 407-413. 10.1089/omi.2012.0124.CrossRef
32.
Li VSW, Yuen ST, Chan TL, Yan HHN, Law WL, Yeung BHY, Chan ASY, Tsui WY, So S, Chen X, Leung SY: Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. Gastroenterology. 2009, 137: 176-187. 10.1053/j.gastro.2009.03.005.CrossRefPubMed
33.
Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T: The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Investig J Tech Methods Pathol. 2001, 81: 1049-1057. 10.1038/labinvest.3780316.CrossRef
34.
Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002, 8: 514-519.PubMed
35.
Lau KM, LaSpina M, Long J, Ho SM: Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000, 60: 3175-3182.PubMed
36.
Daniels G, Gellert LL, Melamed J, Hatcher D, Li Y, Wei J, Wang J, Lee P: Decreased expression of stromal estrogen receptor α and β in prostate cancer. Am J Transl Res. 2014, 6: 140-146.PubMedPubMedCentral
37.
Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON: Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res. 2012, 72: 4672-4681. 10.1158/0008-5472.CAN-12-0228.CrossRefPubMedPubMedCentral
38.
Cha T-L, Zhou BP, Xia W, Wu Y, Yang C-C, Chen C-T, Ping B, Otte AP, Hung M-C: Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005, 310: 306-310. 10.1126/science.1118947.CrossRefPubMed
39.
Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM: Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007, 6: 51-60.CrossRefPubMed
40.
Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005, 4: 1311-1319.CrossRefPubMed
41.
Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL: Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009, 69: 958-966. 10.1158/0008-5472.CAN-08-2216.CrossRefPubMedPubMedCentral
42.
43.
R Development Core Team: R: A language and environment for statistical computing. 2013, Vienna, Austria: R Foundation for Statistical Computing
44.
45.
Heiberger RM: HH:Statistical Analysis and Data Display. 2013, New York, USA: Springer Science
46.
Torsten H, Bretz F, Westfall P, Heiberger RM: Multcomp: Simultaneous Inference in General Parametric Models. Biometrical Journal. 2014, 50: 346-363.
47.
Raykov T, Marcoulides GA: An introduction to applied multivariate analysis. 2008, New York, USA: Routledge
48.
Husson F, Josse J, Le S, Mazt J: FactoMineT: Multivariate Exploratory Data Analysis and Data Mining with R. R package version 1.25. Journal of statistical Software. 2013, 25: 1-18.
49.
Brown TA, Wicker LR: Discriminant Analysis in Handbook of Applied Multivariate Statistics and Mathematical Modeling. Edited by: Tinsley HEA, Brown SD. 2000, California, USA: Elsevier Science & Technology Books
50.
Todorov V, Filzmoser P: rrcov() an Object-Oriented Framework for Robust Multivariate Analysis. Journal of Statistical Software. 2009, 32 (3): 1-47.CrossRef
Metadata
Title
The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters
Authors
Marjolaine Ngollo
Andre Lebert
Aslihan Dagdemir
Gaelle Judes
Seher Karsli-Ceppioglu
Marine Daures
Jean-Louis Kemeny
Frederique Penault-Llorca
Jean-Paul Boiteux
Yves-Jean Bignon
Laurent Guy
Dominique Bernard-Gallon
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-994

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

Research article

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

Study protocol

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung

Research article

Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer

Research article

MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

Research article

High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits